Clinical value of vascular endothelial growth factor and endostatin in urine for diagnosis of bladder cancer

Cheng, Da‐Chuan; Liang, Bin; Li, Yunhui

doi:10.1177/030089161209800614

Cited by 8 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies further illustrate the roles and balance of both positive and negative regulatory factors in tumor angiogenesis [5]. Studies have also indicated the potential of endostatin as a marker of prognostic value in hepatocellular carcinoma [197], bladder cancer [200], cervical cancer [204], colorectal cancer [208], nasopharyngeal carcinoma [211], bronchopulmonary dysplasia [219], pulmonary arterial hypertension [214], traumatic brain injury [217], intermittent claudication in peripheral vascular disease [270], benign vs. malignant ascites [271], Alzheimer’s disease [216], and chronic kidney disease [196]. …”

Section: Discussionmentioning

confidence: 89%

Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications

Walia

Yang

Huang

et al. 2015

Biochimica et Biophysica Acta (BBA) - General Subjects

159

126

View full text Add to dashboard Cite

Background Angiogenesis is the process of neovascularization from pre-existing vasculature and is involved in various physiological and pathological processes. Inhibitors of angiogenesis, administered either as individual drugs or in combination with other chemotherapy, have been shown to benefit patients with various cancers. Endostatin, a 20-kDa C-terminal fragment of type XVIII collagen, is one of the most potent inhibitors of angiogenesis. Scope of review We discuss the biology behind endostatin in the context of its endogenous production, the various receptors to which it binds, and the mechanisms by which it acts. We focus on its inhibitory role in angiogenesis, lymphangiogenesis, and cancer metastasis. We also present emerging clinical applications for endostatin and its potential as a therapeutic agent in the form a short peptide. Major conclusions The delicate balance between pro- and anti-angiogenic factors can be modulated to result in physiological wound healing or pathological tumor metastasis. Research in the last decade has emphasized an emerging clinical potential for endostatin as a biomarker and as a therapeutic short peptide. Moreover, elevated or depressed endostatin levels in diseased states may help explain the pathophysiological mechanisms of the particular disease. General significance Endostatin was once sought after as the ‘be all and end all’ for cancer treatment; however, research throughout the last decade has made it apparent that endostatin’s effects are complex and involve multiple mechanisms. A better understanding of newly discovered mechanisms and clinical applications still has the potential to lead to future advances in the use of endostatin in the clinic.

show abstract

Section: Discussionmentioning

confidence: 89%

Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications

Walia

Yang

Huang

et al. 2015

Biochimica et Biophysica Acta (BBA) - General Subjects

159

126

View full text Add to dashboard Cite

show abstract

“…Studies have also investigated concentrations of endothelial markers involved in angiogenesis, tumour tissues, blood circulation and concentrations in urine. [20][21][22] An increase is seen in concentrations in general circulation of molecules whose expressions increase for various reasons in the vascular endothelium. At the same time, increasingly expressed molecules may also infiltrate urine from the vascular endothelium on the bladder wall.…”

Section: Discussionmentioning

confidence: 99%

The determination of serum and urinary endocan concentrations in patients with bladder cancer

Laloğlu

Aksoy

et al. 2016

Ann Clin Biochem

View full text Add to dashboard Cite

Background Endocan (endothelial cell-specific molecule-1) is a proteoglycan and plays an important role in angiogenesis and inflammation. The aim of this study was to evaluate of serum and urinary concentrations of endothelial cell-specific molecule-1 in bladder cancer. Methods The study included 50 bladder cancer patients, 50 with urinary tract infection and 51 healthy volunteers. Serum and urinary endothelial cell-specific molecule-1 concentrations were measured with enzyme linked immunosorbent assay. Results In bladder cancer group, serum and urinary endothelial cell-specific molecule-1 concentrations were significantly higher than in the healthy subjects ( P = 0.003 and P < 0.0001). Urinary endothelial cell-specific molecule-1 concentrations in cases with urinary tract infection were higher than in healthy volunteers ( P = 0.002). There were no significant differences between bladder cancer and urinary tract infection groups in terms of serum and urinary endothelial cell-specific molecule-1 concentrations. Urinary endothelial cell-specific molecule-1 concentrations were higher than those of corresponding serum endothelial cell-specific molecule-1 concentrations ( P < 0.0001 for bladder cancer and urinary tract infection groups, P = 0.002 for healthy subjects). In bladder cancer group, there was a positive correlation between serum endothelial cell-specific molecule-1 and urinary endothelial cell-specific molecule-1 concentrations ( r = 0.32, P = 0.002). For serum endothelial cell-specific molecule-1, sensitivity and specificity were 50%, and 77%, and for urinary endothelial cell-specific molecule-1, 62%, and 71%, respectively. Conclusion Serum and urinary endothelial cell-specific molecule-1 concentrations increase in bladder cancer. This parameter also increases in serum and urine of cases with urinary tract infection. That urinary endothelial cell-specific molecule-1 values were higher than serum endothelial cell-specific molecule-1 values in all groups may be attributed to direct exfoliation of epithelial cells in bladder to urine.

show abstract

“…32 Studies have also investigated levels of endothelial markers involved in angiogenesis, tumor tissues, blood circulation, and levels in urine. 33,34 Zhang et al 35 showed that endocan is expressed in neogenically active tissue and cell types. They also suggested that endocan may be an important marker in angiogenesis and neogenesis.…”

Section: Discussionmentioning

confidence: 99%

Serum endocan levels in endometrial and ovarian cancers

et al. 2016

View full text Add to dashboard Cite

show abstract

Clinical value of vascular endothelial growth factor and endostatin in urine for diagnosis of bladder cancer

Abstract: Urine levels of VEGF and endostatin may be a clinically useful aid in the diagnosis of bladder cancer, and endostatin but not VEGF is a supplementary prognostic marker for predicting tumor progression.

Cited by 8 publications

References 26 publications

Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications

Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications

The determination of serum and urinary endocan concentrations in patients with bladder cancer

Serum endocan levels in endometrial and ovarian cancers

Contact Info

Product

Resources

About